Novartis ESMO Event Presentation

Pluvicto approved in 37 countries including US and EU; RoW submissions ongoing FDA indication statement PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. More than 7,400 patients treated across 37 countries1 US Other selected countries + EU 1. In commercial setting 7 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation